Sundry Photography / Shutterstock.com
22 October 2020Big PharmaRory O'Neill
Roche secures rights to potential COVID-19 drug
Swiss pharmaceutical company Roche will pay $350 million for the rights to develop and distribute an investigational COVID-19 antiviral outside of the US.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Generics
14 May 2020 Gilead has agreed to license its antiviral remdesivir to five generic makers for distribution during the COVID-19 pandemic.
Big Pharma
2 April 2020 Almost 150 health and poverty activist campaigns, including Médecins Sans Frontières, have urged Gilead Sciences to waive patent and exclusivity rights for potential COVID-19 treatment remdesivir.
Americas
13 November 2020 The US Food and Drug Administration will today announce that it plans to grant a Chinese-owned testing company an exclusive worldwide licence for a US government-owned patent covering a diagnostic test for the rapid detection of COVID-19.
Editor's picks
Editor's picks
Generics
14 May 2020 Gilead has agreed to license its antiviral remdesivir to five generic makers for distribution during the COVID-19 pandemic.
Big Pharma
2 April 2020 Almost 150 health and poverty activist campaigns, including Médecins Sans Frontières, have urged Gilead Sciences to waive patent and exclusivity rights for potential COVID-19 treatment remdesivir.
Americas
13 November 2020 The US Food and Drug Administration will today announce that it plans to grant a Chinese-owned testing company an exclusive worldwide licence for a US government-owned patent covering a diagnostic test for the rapid detection of COVID-19.
Generics
14 May 2020 Gilead has agreed to license its antiviral remdesivir to five generic makers for distribution during the COVID-19 pandemic.
Big Pharma
2 April 2020 Almost 150 health and poverty activist campaigns, including Médecins Sans Frontières, have urged Gilead Sciences to waive patent and exclusivity rights for potential COVID-19 treatment remdesivir.
Americas
13 November 2020 The US Food and Drug Administration will today announce that it plans to grant a Chinese-owned testing company an exclusive worldwide licence for a US government-owned patent covering a diagnostic test for the rapid detection of COVID-19.